Multi-Drug Resistant Gram-Negative Sepsis in Neonates: The Special Role of Ceftazidime/Avibactam and Ceftolozane/Tazobactam

• DOI: 10.20944/preprints202503.0124.v1
• Publication Date: 2025-03-05T05:38:46Z
• Authors: Niki Dermitzaki; Foteini Balomenou; Anastasios Serbis; Natalia Atzemoglou; Lida Giaprou; Maria Baltogianni; Vasileios Giapros
• Keywords: Ceftazidime/avibactam; Tazobactam; Gram-negative bacterial infections; Gram

.Neonatal sepsis is a major cause of morbidity and mortality in neonates. A particular concern the increasing prevalence antibiotic-resistant strains among Neonatal Intensive Care Units (NICUs). significant challenge context neonatal multi-drug resistant infections paucity therapeutic options, as majority newer antibiotics targeting these are not authorized for use Two novel beta-lactam/beta-lactamase inhibitors have recently been approved neonates with infections: ceftazidime/avibactam ceftolozane/tazobactam. These agents demonstrate efficacy against range gram-negative pathogens, including extended-spectrum beta-lactamases (ESBL)-producing carbapenem-resistant Enterobacterales, well multidrug-resistant Pseudomonas aeruginosa. The objective this narrative review to provide summary current knowledge concerning utilization ceftolozane/tazobactam NICU. According existing literature, both shown be highly effective favorable safety profile population, suggesting that they suitable options treatment difficult-to-treat infections.